Animal-free precision collagen peptides via fermentation and hydrolysis

Overview

Defined Bioscience has developed an animal-free platform for precision collagen-supporting peptides. Rather than reproducing full-length animal collagen, the platform designs recombinant collagen-like precursor proteins enriched for sequences that yield orally relevant hydroxyproline-containing peptides such as Pro-Hyp, Hyp-Gly, and Gly-Pro-Hyp. These precursors are produced by microbial fermentation or cell-free expression, with proline hydroxylation engineered where needed, then converted by controlled enzymatic hydrolysis and fractionation into standardized low-molecular-weight peptide ingredients.

This approach addresses growing demand for sustainable, animal-free alternatives to conventional collagen hydrolysates while maintaining the bioactive peptide profile associated with skin health benefits, including increased dermal collagen and elasticity.

Technical specifications

Key features:

• Sequence design of compact collagen-like precursor proteins optimized for efficient expression and controlled peptide release
• Recombinant production in bacterial, yeast, and cell-free systems, with prolyl-4-hydroxylase activity incorporated for hydroxyproline generation
• Controlled enzymatic hydrolysis using food-compatible proteases, coupled with fractionation to maximize target peptides (Pro-Hyp, Hyp-Gly, Gly-Pro-Hyp) and low-molecular-weight product
• LC-MS-based analytical characterization for quantitative peptide composition
• Scalable process development informed by NSF-supported experience in animal-free protein hydrolysis and fractionation

Target applications:

• Food and supplement ingredients for skin health and collagen support
• A standardized, consistent alternative to animal-derived collagen hydrolysates

Technology readiness level

The platform builds on demonstrated capabilities in recombinant protein expression (bacterial, yeast, cell-free), enzymatic hydrolysis, and fractionation. Ongoing validation includes defining the target peptide profile, screening production systems for yield and hydroxylation, optimizing protease and fractionation conditions, testing simulated gastrointestinal stability and cell-based activity for collagen/ECM endpoints, and producing replicate scaled batches to establish yield, reproducibility, preliminary cost of goods, solubility, taste/color, pH/heat stability, and shelf stability. The next phase will select a lead ingredient for pilot-scale production, prototype food/supplement formulation, regulatory planning, and human validation in collaboration with a partner.